In keeping with the key role exerted by VEGF-A for chemoresistance, bevacizumab, a humanized anti-VEGF monoclonal antibody increases the efficacy of chemotherapy for the treatment of metastatic colorectal cancer [41], [42]. Here, VEGFA is linked to metastatic colorectal cancer.